Galen funds migraine med launch

Galen Partners in Stamford has invested $25 million to support the growth of Nautilus Neurosciences Inc., and the upcoming launch of its first commercialized product, Cambia.

“Our investment in Nautilus Neurosciences aligns with our tradition of strategic collaboration and partnership with experienced management teams to help build health care market leaders,” said Zubeen Shroff, managing director of Galen Partners. “The launch of Cambia represents an opportunity to expand our previous success in specialty pharmaceuticals into the field of neurology.”

Nautilus Neurosciences is a neurology-focused pharmaceutical company headquartered in Bridgewater, N.J. Shroff and David Azad, principal at Galen Partners, have joined the Nautilus board of directors.

Nautilus was established in November 2009. Cambia is a migraine treatment just emerging from product-development as a potential treatment for acute pain.

“We are preparing to launch Cambia in the U.S. market in the first half of 2010 and Galen Partners”™ investment enables us to maximize this critical company milestone,” said James Fares, chairman and CEO of Nautilus.